JPRN-UMIN000042502已完成未知
Multicenter retrospective analysis of Elotuzumab, lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma - Multicenter retrospective analysis of Elotuzumab, lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
Japan Red Cross Medical Center0 个研究点目标入组 50 人开始时间: 2020年11月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Cases received ERd as clinical trial.
研究者
相似试验
进行中（未招募）
1 期
A study in patients with HER2-positive breast cancer that has spread and has not responded to one course of anti-cancer therapy.HER2-positive metastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001628-37-NOF. Hoffmann-La Roche Ltd2,003
进行中（未招募）
1 期
A study in patients with HER2-positive breast cancer that has spread and has not responded to one course of anti-cancer therapy.HER2 positive metastatic breast cancerMedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 100000004864EUCTR2012-001628-37-GRF. Hoffmann-La Roche Ltd2,003
进行中（未招募）
1 期
A study in patients with HER2-positive breast cancer that has spread and has not responded to one course of anti-cancer therapy.HER2 positive metastatic breast cancerMedDRA version: 15.0Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001628-37-ESF. Hoffmann-La Roche Ltd (representado en España por Roche Farma, S.A)1,000
进行中（未招募）
1 期
A study in patients with HER2-positive breast cancer that has spread and has not responded to one course of anti-cancer therapy.EUCTR2012-001628-37-ISF. Hoffmann-La Roche Ltd2,003
已完成
3 期
A multicenter, single arm study of trastuzumab emtansine (T-DM1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti-HER2 and chemotherapy-based treatmentHER2 positive locally advanced or metastatic breast cancer10006291breast cancerNL-OMON39697Roche Nederland B.V.30